This study by DZHK researchers from the Berlin partner site aimed to address the lack of effective treatments for heart failure by testing a new delivery method for a promising peptide therapy. The researchers used a unique technology called LungToHeartNIM to deliver a peptide targeting a specific heart failure mechanism. The study was conducted in pigs with heart failure, where the inhaled therapy significantly improved heart function, reversed heart remodelling and reduced lung congestion without causing any adverse effects. This suggests that the LungToHeartNIM technology could be a breakthrough treatment for heart failure patients by effectively delivering therapeutic peptides directly to the heart.
Link to the original publication: Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure